Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome‐wide expression studies
Open Access
- 27 June 2006
- journal article
- Published by Wiley in Molecular Microbiology
- Vol. 61 (3) , 704-722
- https://doi.org/10.1111/j.1365-2958.2006.05235.x
Abstract
Summary: Candida glabrata emerged in the last decade as a common cause of mucosal and invasive fungal infection, in large part due to its intrinsic or acquired resistance to azole antifungals such as fluconazole. In C. glabrata clinical isolates, the predominant mechanism behind azole resistance is upregulated expression of multidrug transporter genes CDR1 and PDH1. We previously reported that azole‐resistant mutants (MIC ≥ 64 μg ml−1) of strain 66032 (MIC = 16 μg ml−1) similarly show coordinate CDR1‐PDH1 upregulation, and in one of these (F15) a putative gain‐of‐function mutation was identified in the single homologue of Saccharomyces cerevisiae transcription factors Pdr1–Pdr3. Here we show that disruption of C. glabrata PDR1 conferred equivalent fluconazole hypersensitivity (MIC = 2 μg ml−1) to both F15 and 66032 and eliminated both constitutive and fluconazole‐induced CDR1‐PDH1 expression. Reintroduction of wild‐type or F15 PDR1 fully reversed these effects; together these results demonstrate a role for this gene in both acquired and intrinsic azole resistance. CDR1 disruption had a partial effect, reducing fluconazole trailing in both strains while restoring wild‐type susceptibility (MIC = 16 μg ml−1) to F15. In an azole‐resistant clinical isolate, PDR1 disruption reduced azole MICs eight‐ to 64‐fold with no effect on sensitivity to other antifungals. To extend this analysis, C. glabrata microarrays were generated and used to analyse genome‐wide expression in F15 relative to its parent. Homologues of 10 S. cerevisiae genes previously shown to be Pdr1–Pdr3 targets were upregulated (YOR1, RTA1, RSB1, RPN4, YLR346c and YMR102c along with CDR1, PDH1 and PDR1 itself) or downregulated (PDR12); roles for these genes include small molecule transport and transcriptional regulation. However, expression of 99 additional genes was specifically altered in C. glabrata F15; their roles include transport (e.g. QDR2, YBT1), lipid metabolism (ATF2, ARE1), cell stress (HSP12, CTA1), DNA repair (YIM1, MEC3) and cell wall function (MKC7, MNT3). These azole resistance‐associated changes could affect C. glabrata tissue‐specific virulence; in support of this, we detected differences in F15 oxidant, alcohol and weak acid sensitivities. C. glabrata provides a promising model for studying the genetic basis of multidrug resistance and its impact on virulence.Keywords
This publication has 48 references indexed in Scilit:
- Candida glabrata PDR1 , a Transcriptional Regulator of a Pleiotropic Drug Resistance Network, Mediates Azole Resistance in Clinical Isolates and Petite MutantsAntimicrobial Agents and Chemotherapy, 2006
- Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapyJournal of Infection, 2006
- Improved oral hygiene and Candida species colonization level in geriatric patientsOral Diseases, 2005
- Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent CasesJournal of Clinical Microbiology, 2005
- Genome evolution in yeastsNature, 2004
- Mechanism of Increased Fluconazole Resistance in Candida glabrata during ProphylaxisAntimicrobial Agents and Chemotherapy, 2004
- In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance programDiagnostic Microbiology and Infectious Disease, 2004
- Breakthrough Candidemia in Patients with Cancer Differs from De Novo Candidemia in Host Factors andCandidaSpecies But Not IntensityInfection Control & Hospital Epidemiology, 2002
- Prospective Study of Candida Species in Patients at a Comprehensive Cancer CenterAntimicrobial Agents and Chemotherapy, 2001
- The Multidrug Resistance-associated Protein (MRP) Subfamily (Yrs1/Yor1) of Is Important for the Tolerance to a Broad Range of Organic AnionsJournal of Biological Chemistry, 1996